AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
FDA Greenlights Aldosterone Synthase Inhibitor, Opening a New Front in Hypertension Treatment
The FDA has approved an aldosterone synthase inhibitor for hypertension, adding a new mechanism to the blood pressure treatment toolkit. The decision matters because it targets a hormonal pathway long seen as promising but hard to drug cleanly.
Isomorphic Labs’ $2.1 Billion Round Signals AI Drug Discovery Is Entering Its Industrial Phase
Isomorphic Labs’ massive new financing is more than a headline-grabbing raise: it is a strong signal that investors believe AI-native drug discovery can become a durable platform business, not just a research experiment. The deal also underscores how concentrated the bet has become around a handful of companies that claim they can compress early discovery timelines and improve hit rates.
AI in Drug Development Is Moving from Hype to Workflow, According to 2026 Trend Analysis
AlphaSense’s 2026 trend analysis argues that AI in drug development is entering a more practical phase. The emphasis is shifting from broad promise to specific workflow gains across discovery, design, and development.
Merck’s $1 Billion Google Cloud Deal Shows Pharma Is Betting Big on AI Infrastructure
Merck’s reported $1 billion deal with Google Cloud highlights the scale of investment pharma is willing to make in AI infrastructure. The agreement suggests that data, compute, and platform integration are becoming strategic assets in drug development.
Eli Lilly Deepens Its AI Drug Discovery Bet with Expanded Insilico Partnership
Eli Lilly is expanding its partnership with Insilico Medicine, reinforcing the view that big pharma sees AI-driven discovery as a strategic capability, not a side experiment. The deal is also a sign that established drugmakers increasingly prefer to partner for AI advantage rather than build everything internally.
AI in Drug Discovery Is Now a $160 Billion Story, but the Real Market Is Still Being Built
A new forecast pegs the AI drug-discovery market at $160.49 billion by 2035, reflecting intense investor interest in the space. But forecasts this large also reveal how much of the market remains aspirational rather than proven.
OpenAI’s Early Drug-Discovery Model Signals the Next AI Arms Race in Pharma
OpenAI’s push into early drug discovery underscores how general-purpose AI companies are moving deeper into life sciences. The move raises the stakes for incumbents like Google, cloud vendors, and biotech-focused AI startups that have spent years building domain-specific platforms.
AI Is Rewriting the Drug Labeling Playbook
Drug labeling is emerging as a high-value AI use case, with companies exploring tools that can manage the volume, complexity, and constant change of regulatory content. The shift could make labeling faster and more consistent, but it also raises questions about governance and validation.
AI Is Moving Into Drug Labeling, Turning a Compliance Burden Into a Data Problem
AI is increasingly being used in drug labeling workflows, an area long dominated by manual review and complex regulatory oversight. The shift could reduce bottlenecks, but only if companies treat labeling as a governed data system rather than a static document.
Novo Nordisk and OpenAI Strike a Broad AI Pact for Drug Discovery and Beyond
Novo Nordisk’s agreement with OpenAI is a sign that major drugmakers are moving AI from isolated research experiments into core R&D operations. The deal appears designed to spread AI across discovery, manufacturing, and corporate workflows, not just one lab team.
Novo Nordisk and OpenAI’s Alliance Shows AI Drug Discovery Becoming a Core Pharma Capability
Another account of the Novo Nordisk-OpenAI deal reinforces how widely the partnership is being interpreted as a turning point for pharma AI. The significance lies not just in the collaboration itself, but in how quickly the industry is converging on AI as essential infrastructure.
Eli Lilly and Insilico strike AI drug discovery deal
Eli Lilly and Insilico’s new partnership adds another major pharma validation point for AI-led discovery. The deal highlights how large drugmakers are increasingly willing to pay for external AI capabilities rather than build every piece internally.
Roche and NVIDIA Build the Pharma Industry’s Largest AI Factory
Roche’s new collaboration with NVIDIA signals how quickly drug development is becoming an infrastructure game, not just a software one. By pairing pharmaceutical data with industrial-scale compute, the companies are betting that AI advantage will come from owning the entire pipeline from model training to candidate selection.
Insilico-Lilly deal shows big pharma still sees AI as a pipeline multiplier, not a side bet
A reported multibillion-dollar deal between Insilico Medicine and Eli Lilly underscores continued pharmaceutical appetite for AI-enabled drug discovery. The scale suggests AI is being valued not as experimental tooling but as a potentially material lever on pipeline speed, hit quality, and portfolio optionality.
Pharma’s AI boom is opening a quieter cybersecurity front
Observer’s look at security risks inside pharma’s AI push highlights an issue that has lagged behind the sector’s growth narrative. As drug makers centralize proprietary biology, models, and workflows, AI security is emerging as a strategic and regulatory vulnerability rather than an IT afterthought.
Big Pharma Is Placing Larger, Narrower Bets in AI Drug Discovery
Korea JoongAng Daily reports that pharmaceutical companies are making bigger bets on fewer AI-enabled discovery projects. The pattern suggests the industry is moving from experimentation with broad AI portfolios toward concentrated investment in programs with clearer biological rationale and execution pathways.
AI-Native Trial Platform Evinova Expands With AstraZeneca and Astellas Deals
Evinova, the digital health company launched by AstraZeneca, has added Astellas and AstraZeneca partnerships to deploy its AI-native platform for clinical development. The story is important because it highlights a quieter but commercially important healthcare AI trend: using AI to improve trial design, execution, and operational efficiency rather than only molecule discovery or front-line diagnosis.
AI in Drug Discovery: 2025 in Review — Insilico Medicine Hits Phase IIa Milestone
Insilico Medicine achieved the first positive Phase IIa results for a fully AI-designed drug, while the Recursion-Exscientia merger created an end-to-end AI drug discovery platform. Over 200 AI-discovered drugs are now in development.
Insilico and Servier Sign $888 Million AI Cancer Discovery Pact
Insilico Medicine and Servier have entered a cancer R&D collaboration valued at up to $888 million, with Insilico leading AI-driven discovery for challenging oncology targets and Servier handling clinical validation and commercialization. The deal underscores how major drugmakers are increasingly treating AI not as a side capability but as a front-end engine for target selection and molecule generation.
AI Drug Discovery Reaches 173 Active Clinical Programs With New FDA Framework
A comprehensive analysis counts 173 active AI-discovered drug programs in clinical development, supported by an evolving FDA framework for credibility assessment of AI models used in drug discovery.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.